刺络放血疗法结合穴位注射治疗椎间盘源性下腰痛的临床随机对照研究

注册号:

Registration number:

ChiCTR-IPR-17010901 

最近更新日期:

Date of Last Refreshed on:

2017-03-17 15:36:56 

注册时间:

Date of Registration:

2017-03-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

刺络放血疗法结合穴位注射治疗椎间盘源性下腰痛的临床随机对照研究

Public title:

Treatment of discogenic low back pain with pricking blood therapy combined with acupoint injection: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

刺络放血疗法结合穴位注射治疗椎间盘源性下腰痛的临床随机对照研究

Scientific title:

Treatment of discogenic low back pain with pricking blood therapy combined with acupoint injection: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙保国 

研究负责人:

孟君 

Applicant:

Sun baoguo 

Study leader:

Meng jun 

申请注册联系人电话:

Applicant telephone:

+86 13316134352

研究负责人电话:

Study leader's
telephone:

+86 13316134352

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sunbaoguo666@126.com

研究负责人电子邮件:

Study leader's E-mail:

sunbaoguo666@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市中山二路58号

研究负责人通讯地址:

广东省广州市中山二路58号

Applicant address:

58 Second Zhongshan Road, Guangzhou, Guangdong, China

Study leader's address:

58 Second Zhongshan Road, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

510080

研究负责人邮政编码:

Study leader's postcode:

510080

申请人所在单位:

中山大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Sun Yat-sen University University

研究负责人所在单位:

中山大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Sun Yat-sen University University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2017-017

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第一医院临床科研和实验动物伦理委员会

Name of the ethic committee:

Ethics committee for clinical research and experimental animals of the First Affiliated Hospital of Sun Yat-sen University University

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Sun Yat-sen University University

研究实施负责(组长)单位地址:

广东省广州市中山二路58号

Primary sponsor's address:

58 Second Zhongshan Road, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市(越秀区)

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第一医院

具体地址:

广东省广州市中山二路58号

Institution
hospital:

The First Affiliated Hospital of Sun Yat-sen University University

Address:

58 Second Zhongshan Road, Guangzhou, Guangdong, China

经费或物资来源:

自筹

Source(s) of funding:

Funds independently

研究疾病:

椎间盘源性下腰痛  

Target disease:

discogenic low back pain

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟通过开放标签的随机对照研究,评价刺络放血疗法结合穴位注射治疗椎间盘源性下腰痛的安全性、有效性。  

Objectives of Study:

The purpose of this study was to evaluate the safety and efficacy of pricking blood therapy combined with acupoint injection in the treatment of discogenic low back pain.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①有脊柱外科手术史者; ②有严重脊柱创伤史者; ③影像学所见有脊柱骨质肿瘤、结核、骨质疏松等病症者; ④合并心血管、脑血管、造血、消化系统等严重疾病或精神病者; ⑤妊娠期及哺乳期妇女;⑥肝肾功能异常者; ⑦有其他自身免疫性疾病、变态反应性疾病和急慢性感染者; ⑧慢性皮肤疾病、操作区皮肤溃疡、伤口疤痕等;⑨研究者认为因其他原因不适合参加本临床试验者。

Exclusion criteria:

1. A history of spinal surgery;
2. History of severe spinal trauma;
3. The imaging findings included spinal bone tumor, tuberculosis, osteoporosis and other diseases;
4. Cardiovascular diseases such as cardiovascular and digestive system and other serious diseases;
5. Pregnant and lactating women;
6. Liver and kidney dysfunction;
7. Other autoimmune diseases, allergic diseases and acute and chronic infections;
8. Chronic skin disease or operation area with skin ulcer wound scar;
9. The researchers did not think it would be appropriate to participate in this clinical trial.

研究实施时间:

Study execute time:

From 2017-04-01 00:00:00 To 2018-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-04-01 00:00:00 To 2017-10-01 00:00:00

干预措施:

Interventions:

组别:

治疗组

样本量:

60

Group:

Treatment group

Sample size:

干预措施:

刺络放血疗法结参附注射液合穴位注射

干预措施代码:

Intervention:

Pricking blood therapy combined with acupoint injection with shenfu injection

Intervention code:

组别:

对照组

样本量:

60

Group:

Contol group

Sample size:

干预措施:

塞来昔布胶囊

干预措施代码:

Intervention:

Celecoxib capsules

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第一医院 

单位级别:

三甲医院 

Institution
hospital:

The First Affiliated Hospital of Sun Yat-sen University University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

VAS疼痛程度

指标类型:

主要指标

Outcome:

VAS pain level

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Oswestry功能障碍指数

指标类型:

主要指标

Outcome:

Oswestry dysfunction index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子-α

指标类型:

次要指标

Outcome:

TNF-α

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-1

指标类型:

次要指标

Outcome:

IL-1

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-6

指标类型:

次要指标

Outcome:

IL-6

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮损愈合情况

指标类型:

副作用指标

Outcome:

Skin healing

Type:

Adverse events

测量时间点:

测量方法:

观察

Measure time point of outcome:

Measure method:

Observing

指标中文名:

过敏反应

指标类型:

副作用指标

Outcome:

Allergic reaction

Type:

Adverse events

测量时间点:

测量方法:

观察

Measure time point of outcome:

Measure method:

Observing

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

静脉血

组织:

Sample Name:

Veinal blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者采用随机数字法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers used random numbers to generate random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

采用中国临床试验注册中心网站公开数据,网址:http://www.chictr.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

China clinical trial registration center website data, web site:http://www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据保存采用纸质版病例报告表和excel软件进行,原始数据上传于采用中国临床试验注册中心网站。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data were stored in a paper version of the case report form and Excel software. The original data were uploaded on the website of China clinical trial registration center.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2017-03-17 15:36:56